These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 25354531)

  • 1. Novel syngeneic mouse mammary carcinoma cell lines from aggressive ErbB2/Neu-overexpressing/PTEN-deficient tumors.
    Wang Q; Ding H; Wang H; Li P; Liu B; Zhang K
    Oncol Rep; 2015 Jan; 33(1):179-84. PubMed ID: 25354531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Addition of the Akt inhibitor triciribine overcomes antibody resistance in cells from ErbB2/Neu-positive/PTEN-deficient mammary tumors.
    Wang Q; Ding H; Liu B; Li SH; Li P; Ge H; Zhang K
    Int J Oncol; 2014 Apr; 44(4):1277-83. PubMed ID: 24452693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Generation and comparison of two genetically engineered mouse models of ErbB2/Neu positive-PTEN deficient breast cancer].
    Wang QF; Ding H; Liu BR; Zhang K
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2014 Jul; 43(4):427-33. PubMed ID: 25187457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PTEN deficiency in a luminal ErbB-2 mouse model results in dramatic acceleration of mammary tumorigenesis and metastasis.
    Schade B; Rao T; Dourdin N; Lesurf R; Hallett M; Cardiff RD; Muller WJ
    J Biol Chem; 2009 Jul; 284(28):19018-26. PubMed ID: 19435886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ErbB2-positive mammary tumors can escape PI3K-p110α loss through downregulation of the Pten tumor suppressor.
    Simond AM; Rao T; Zuo D; Zhao JJ; Muller WJ
    Oncogene; 2017 Oct; 36(43):6059-6066. PubMed ID: 28783168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted Pten deletion plus p53-R270H mutation in mouse mammary epithelium induces aggressive claudin-low and basal-like breast cancer.
    Wang S; Liu JC; Kim D; Datti A; Zacksenhaus E
    Breast Cancer Res; 2016 Jan; 18(1):9. PubMed ID: 26781438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells.
    Kim A; Liu B; Ordonez-Ercan D; Alvarez KM; Jones LD; McKimmey C; Edgerton SM; Yang X; Thor AD
    Breast Cancer Res; 2005; 7(5):R708-18. PubMed ID: 16168116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In MMTV-Her-2/neu transgenic mammary tumors the absence of caveolin-1-/- alters PTEN and NHERF1 but not β-catenin expression.
    Cuello-Carrión FD; Cayado-Gutiérrez N; Natoli AL; Restall C; Anderson RL; Nadin S; Alvarez-Olmedo D; Castro GN; Gago FE; Fanelli MA; Ciocca DR
    Cell Stress Chaperones; 2013 Sep; 18(5):559-67. PubMed ID: 23397229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers.
    Xia W; Husain I; Liu L; Bacus S; Saini S; Spohn J; Pry K; Westlund R; Stein SH; Spector NL
    Cancer Res; 2007 Feb; 67(3):1170-5. PubMed ID: 17283152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Her-2/neu overexpression induces NF-kappaB via a PI3-kinase/Akt pathway involving calpain-mediated degradation of IkappaB-alpha that can be inhibited by the tumor suppressor PTEN.
    Pianetti S; Arsura M; Romieu-Mourez R; Coffey RJ; Sonenshein GE
    Oncogene; 2001 Mar; 20(11):1287-99. PubMed ID: 11313873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Attenuation of PI3K/Akt-mediated tumorigenic signals through PTEN activation by DNA vaccine-induced anti-ErbB2 antibodies.
    Porzia A; Lanzardo S; Citti A; Cavallo F; Forni G; Santoni A; Galandrini R; Paolini R
    J Immunol; 2010 Apr; 184(8):4170-7. PubMed ID: 20220087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein tyrosine phosphatase 1B deficiency or inhibition delays ErbB2-induced mammary tumorigenesis and protects from lung metastasis.
    Julien SG; Dubé N; Read M; Penney J; Paquet M; Han Y; Kennedy BP; Muller WJ; Tremblay ML
    Nat Genet; 2007 Mar; 39(3):338-46. PubMed ID: 17259984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of STAT1 from mouse mammary epithelium results in an increased Neu-induced tumor burden.
    Klover PJ; Muller WJ; Robinson GW; Pfeiffer RM; Yamaji D; Hennighausen L
    Neoplasia; 2010 Nov; 12(11):899-905. PubMed ID: 21076615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene expression profiling of cancer progression reveals intrinsic regulation of transforming growth factor-beta signaling in ErbB2/Neu-induced tumors from transgenic mice.
    Landis MD; Seachrist DD; Montañez-Wiscovich ME; Danielpour D; Keri RA
    Oncogene; 2005 Aug; 24(33):5173-90. PubMed ID: 15897883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PTEN loss and KRAS activation leads to the formation of serrated adenomas and metastatic carcinoma in the mouse intestine.
    Davies EJ; Marsh Durban V; Meniel V; Williams GT; Clarke AR
    J Pathol; 2014 May; 233(1):27-38. PubMed ID: 24293351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of LKB1 expression reduces the latency of ErbB2-mediated mammary gland tumorigenesis, promoting changes in metabolic pathways.
    Andrade-Vieira R; Xu Z; Colp P; Marignani PA
    PLoS One; 2013; 8(2):e56567. PubMed ID: 23451056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioluminescent human breast cancer cell lines that permit rapid and sensitive in vivo detection of mammary tumors and multiple metastases in immune deficient mice.
    Jenkins DE; Hornig YS; Oei Y; Dusich J; Purchio T
    Breast Cancer Res; 2005; 7(4):R444-54. PubMed ID: 15987449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gemini vitamin D analog suppresses ErbB2-positive mammary tumor growth via inhibition of ErbB2/AKT/ERK signaling.
    Lee HJ; So JY; DeCastro A; Smolarek A; Paul S; Maehr H; Uskokovic M; Suh N
    J Steroid Biochem Mol Biol; 2010 Jul; 121(1-2):408-12. PubMed ID: 20304052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of Nrdp1 enhances ErbB2/ErbB3-dependent breast tumor cell growth.
    Yen L; Cao Z; Wu X; Ingalla ER; Baron C; Young LJ; Gregg JP; Cardiff RD; Borowsky AD; Sweeney C; Carraway KL
    Cancer Res; 2006 Dec; 66(23):11279-86. PubMed ID: 17145873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor heterogeneity, aggressiveness, and immune cell composition in a novel syngeneic PSA-targeted Pten knockout mouse prostate cancer (MuCaP) model.
    van Duijn PW; Marques RB; Ziel-van der Made ACJ; van Zoggel HJAA; Aghai A; Berrevoets C; Debets R; Jenster G; Trapman J; van Weerden WM
    Prostate; 2018 Sep; 78(13):1013-1023. PubMed ID: 30133757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.